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ABSTRACT
Objective: Several factors including disease condition and different procedures could alter 
pharmacokinetic profile of drugs in critically ill patients. For optimizing patient’s outcome, 
changing in dosing regimen is necessary. Extracorporeal Membrane Oxygenation (ECMO) is 
one of the procedures which could change pharmacokinetic parameters.The aim of this review 
was to evaluate the effect of ECMO support on pharmacokinetic parameters and subsequently 
pharmacotherapy.
Method: A systematic review was conducted by reviewing all papers found by searching 
following key words; extracorporeal membrane oxygenation, ECMO, pharmacokinetic and 
pharmacotherapy in bibliography database.
Results: Different drug classes have been studied; mostly antibiotics. Almost all of the studies 
have been performed in neonates (as a case series). ECMO support is associated with altered 
pharmacokinetic parameters that may result in acute changes in plasma concentrations with 
potentially unpredictable pharmacological effect. Altreation in volume of distribution, protein 
binding, renal or hepatic clearance and sequestration of drugs by ECMO circuit may result 
in higher or lower doses requirement during ECMO. As yet, definite dosing guideline is not 
available.
ECMO is extensively used recently for therapy and as a procedure affects pharmacokinetics 
profile along with other factors in critically ill patients. For optimizing the pharmacodynamic 
response and outcome of patients, drug regimen should be individualized through therapeutic 
drug monitoring whenever possible. 
Keywords:  Extracorporeal membrane oxygenation (ECMO), Pharmacokinetics, Systematic 
review.
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INTRODUCTION
Extracorporeal Membrane Oxygenation (ECMO) 
is an advanced life support system for providing 
respiratory and cardiorespiratory support for patients 
of all ages who have failed conventional intensive 
care management. This technique was adopted from 
cardiopulmonary bypass used in open heart surgery 
and provides passive support of gas exchange 
and perfusion, thereby allowing implementation 
and optimisation of other forms of therapy to aid 
organ recovery (1-3). Extracorporeal lung assist 
(ECLA), extracorporeal life support (ECLS), and 
extracorporeal CO2 removal (ECCOR) are other 
synonymes of ECMO.
A variety of diagnosis, including Meconium 
Aspiration Syndrome (MAS), congenital 
diaphragmatic hernia (CDH), persistent pulmonary 
hypertension of the newborn (PPHN), respiratory 
distress syndrome, cardiac anomaly, sepsis or 
pneumonia are the reasons for performing ECMO 
in neonates (4-6). Use of ECMO in adult patients 
both as a treatment for acute respiratory and 
cardiorespiratory failure or as a bridge to either 
cardiac transplantation or placement of a ventricular 
assist device is necessary (7-11).
In the cases of irreversible respiratory or cardiac 
failure and any contraindication for anticoagulation, 
ECMO should not be started. Advanced age, morbid 
obesity, neurologic dysfunction or poor pre-existing 
functional status are other exclusion conditions (7; 
12).
There are two types of ECMO-Venoarterial (VA) and 
Venovenous (VV). Generally during ECMO, a large 
volume of blood is extracted from the venous system 
(large central vein) and circulated outside the body 
by a mechanical pump (centrifugal or roller), where 
the blood passes through an oxygenator and heat 
exchanger. In the oxygenator, hemoglobin becomes 
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Finally the blood is returned into the native vascular 
system (venous system near the right atrium in VV 
and arterial system in the aorta in VA ECMO) (3; 
13).
In VV ECMO the circulation is powered entirely by 
native cardiac function, so it just provides support 
for respiratory failure, but in VA ECMO blood 
bypassing the heart and lungs, so it can be used 
for both respiratory and cardiac failures. Avoiding 
arterial cannulation and maintaining pulsatile blood 
flow  to  the  patient  are  other  advantages  of  VV 
ECMO (2; 11; 13). 
Depending on diagnosis and age group, ECMO 
increase survival rate to 50-95% in comparison 
with conventional treatment such as mechanical 
ventilation with high inspired fractional oxygen or 
instillation of surfactant. Survival rate for children 
requiring ECMO for respiratory support is 63%, 
for children needing cardiac support is 55% and for 
adults it is nearly 50 % (14-17).
Critically  ill  patient’s  exihibit  a  range  of  organ 
dysfunctions and often require therapeutic 
support with a variaty of procedures including 
mechanical ventilation and renal replacement 
therapy. These procedures along with underlying 
pathophysiological process result in changes in 
major pharmacokinetic parameters such as volume 
of distribution (Vd) and clearance (CL)  in critically 
ill patients (18-28). Several aspects of ECMO 
(as a procedure in ICU) such as sequestration of 
drug by ECMO circuit, increase in the volume of 
distribution, alteration in renal and hepatic blood 
flow,  flow  rate  of  the  system  and  other  factors 
change pharmacokinetic parameters of drugs (13; 
29-34). Of different drug classes some of them 
such as sedative (propofol) (35) or vasoprossors 
(norepinephrine) (36) could be easily titrated 
according  to  patient’s  response  but  for  others 
especially antibiotics (cefepim, vancomycin) (37, 
38) titration of dose based on patient response rate 
is not possible, thus applying pharmacokinetic 
principles in selection of drug and dosing regimen 
is crucial for optimization the pharmacodynamic 
response and outcome of patients.
The aim of this study is to review the effect of 
ECMO support on pharmacokinetic parameters and 
optimal dosing regimen during ECMO.
METHODS
In order to provide enough databases about the 
subject, a systematic search utilizing Pubmed, 
Scopus, Googel Scholar and Embase database 
was carried out. The initial search terms were 
“extracorporeal membrane oxygenation”, 
“ECMO”, pharmacokinetic and pharmacotherapy, 
without narrowing or limiting search elements to 
find the most relevant literatures about the subject. 
References from each article were also evaluated for 
relevancy of inclusion in the study. All papers were 
reviewed to omit irrelevant or duplicate papers, 
and then their data were extracted into tables and 
summarized.
RESULTS AND DISCUSSION
As summarized in table 1, different drug classes 
have been studied in patients under ECMO. Almost 
all of these studies were performed in neonates and 
usually without control groups and on the basis 
of pharmacokinetic parameters such as volume 
of distribution, clearance and half life a dose or 
method for monitoring was recommended. Small 
sample size, differences in ECMO technique and 
equipment, complexity of patients with lack of 
uniform diagnosis, different methods for evaluation 
of kinetic were limitations of these studies 
which complicate clinical judgment. Also due to 
inadequate  investigation,  difinit  recommendation 
for adults is not possible. Antibiotics, sedatives, 
analgesics, anticonvulsants are the most studied 
drugs in patients under ECMO (Table 1). 
Mixing of priming volume with the patient’s own 
blood volume increase effective circulating volume 
and decrease in the total blood concentration is the 
immediate effect of this acute hemodilution (13; 
29). The pharmacological impact depend on the 
apparent Vd of the drugs, the degree of protein 
binding and the extent of equilibration between 
tissue and plasma concentrations on initiation 
of ECMO (13; 3 4; 39). Drugs with large Vd e.g. 
amiodarone (40) would be expected to show only a 
slight changes because drug back diffuse to plasma 
from large tissue reservoirs. In contrast, a drug with 
a small Vd such as gentamicin may be significantly 
affected and the resultant enlarged apparent Vd may 
affect the elimination rate of the drug. Depletion of 
the plasma protein such as albumin during acute 
hemodilution may affect plasma and tissue protein 
binding and plasma concentrations of drugs, but it 
is just a transient effect because transfusing blood 
and related products such as albumin will normalize 
the effects of hemodilution (39).
Changes  in  blood  flow  affect  clearance  of  drugs 
during ECMO. VV ECMO result in pulsatile 
blood flow, whereas VA ECMO at high flow rates 
(>100ml/kg/min) may produce non-pulsatile flow. 
Non-pulsatile flow can alter perfusion of tissues, 
reduce capillary circulation and aerobic metabolism 
(41; 42). The kidneys interpret pulsless blood flow 
as hypotension and activate the renin-angiotensin 
system which result in reduced urine production and 
impaired  sodium  excretion.  Regional  blood  flow 
changes in the liver can also affect drug clearance, 
in particular those drugs with a high extraction ratio 
e.g. propranolol (43). Perfusion of tissues may also 
be altered as a result of activation of Systematic 
Inflammatory Response System (SIRS) releasing a 
variety of autonomic, endocrine and local cytokine 
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that may affect not only tissue distribution of drugs 
but also clearance mechanism as well.
The loss of drugs to the ECMO circuit (to tube 
or oxygenator) depend on the surface area in 
contact with the circulating fluid and extent of any 
physiochemical interactions between individual 
drugs and the different plastic components of the 
circuit (31, 44). Based on studies for evaluation 
of  drug  sequestration  during  ECMO,  significant 
sequestration of opioids (alfentanil, fentanyl, 
morphine), benzodiazepins (midazolam, diazepam, 
lorazepam), glyceryl nitrate and propofol, has been 
reported and it has also been described that ECMO 
circuit decrease levels of phenobarbital, heparin, 
vancomycin, gentamicin and phenytoin delivery 
(31; 44; 45). Voriconazol, cefazolin and ampicillin 
are also sequestered during ECMO and therefore 
their therapeutic concentrations cannot be definite.
Gentamicin is the most well studied drug in patients 
under ECMO (table 1). All of studies on gentamicin 
have been performed on neonates. None of studies 
had control groups and only pharmacokinetic 
parameters have been compared before and after 
stopping ECMO. Usually dose rate of 2.5 mg/kg 
every 12 hrs was administered for infants under 
ECMO, blood samples were collected after steady 
state (usually 3 days), pharmacokinetic parameters 
were evaluated and correlation between ages, 
weight, and serum creatinin had been evaluated. 
Cohn et al. (59) compared data for patients on ECMO 
and after discontinuation of ECMO. They reported 
significant increase in Vd and half life and decrease 
in clearance for patients on ECMO and a dose rates 
of about 25% lower than usual and longer dosing 
intervals for patients undergoing ECMO therapy. 
A retrospective study on 29 neonates receiving 
gentamicin during ECMO and a comparison of 
kinetic parameters with non–ECMO population 
showed that Vd (0.66± 0.2 L/kg) was median in 
ECMO groups in comparison with non- ECMO 
patients (0.58-0.75 L/kg) but half life increased 
significantly  during  ECMO  (10.4  hour)  (57). 
According to results of all studies on gentamicin 
during  ECMO  (table  1),  Vd  was  significantly 
higher  and  clearance  was  significantly  lower  in 
comparison with non-ECMO patients; because 
ECMO especially non-pulsatile method results 
in  decrease  of  renal  blood  flow  and  Glomerulal 
Filtration Rate (GFR) and finally reduction in renal 
clearance. Gentamicin is a hydrophilic drug and 
increase in extracellular volume following ECMO 
result in an increase in Vd. To achieve therapeutic 
levels, a maintenance dose of 2.5 mg/kg every 18 
hours was recommended in neonates without renal 
impairment. 
Vancomycin pharmacokinetic during ECMO has 
also been described. Buck et al. (54) conducted a 
retrospective study in 15 neonates who received 
vancomycin during ECMO and compared 
pharmacokinetic data with matched control. The 
most frequent regiments prescribed in both groups 
were 10 mg/kg every 8 hrs. The data was analysed 
using a one compartment model and showed a Vd 
of 0.45 ± 0.18 L/kg, half life of 8.29 ± 2.23 hrs 
and CL of 0.79 L/kg/h in ECMO neonates. The 
parameters were not significantly different in the 
control group but half life was shorter. The author 
recommended that empiric vancomycin regiments 
incorporate a longer dosing interval than the 6-8 
hrs which is commomly recommended for the 
infants. Results of other studies compared kinetic 
parameters with non-ECMO population show that 
Vd and half life were higher and clearance was 
lower in ECMO patients. However Hoie et al. (53) 
reported no difference in kinetic profile. In all above 
studies the numbers of neonates were small (6-12 
neonates). In one study conducted in adults, there 
were no significant differences in pharmacokinetic 
parameters between ECMO and non-ECMO groups 
(56). Therefore due to differences in methods and 
populations, recommendation of a dosing regimen 
is not possible especially in adults.
In other studies on antibiotic in ECMO patients, 
despite higher Vd in ECMO patients, standard dose 
of cefotaxime was recommended in neonates under 
ECMO (61).Monitoring the level of voriconazol in 
patients under ECMO has been suggested because 
this drug is sequestered during ECMO. Caspofungin 
could be prescribed with the same dosage in ECMO 
patients (63).
Sedatives and analgesics are important classes of 
drugs which are extensively used in critically ill 
especially ECMO patients. For short term procedure 
fentanyl may be suitable for analgesia because this 
drug is extensively bind to ECMO circuit after 
24 hrs and usually higher doses are required to 
achieve desired therapeutic effect during ECMO. 
In comparison, morphine concentrations were well 
preserved during ECMO in both crystalloid or 
blood primed circuit, therefore it is a preferred drug 
for prolonged period, However results of a study 
(47) has shown that morphine clearance which 
decreases (even to half) during ECMO leads to an 
increase in serum concentration and some neonates 
experience withdrawal syndrome after ECMO 
discontinuation, authors suggested that increase in 
hepatic blood flow might be a reason for decrease 
in clearance. On the other hand Jeroen et al. (66) 
concluded that morphine clearance was lower than 
non ECMO but increased rapidly and after 14 days 
was equal to the control group. Size and age are 
factors that significantly affect morphine clearance 
but pump flow or simultaneous drugs have no effect. 
Although initial morphine dosing may be guided by 
age and weight, but clearance and Vd change during 
prolonged ECMO which suggest that morphine 
therapy should be subsequently guided by clinical 
monitoring(46-48). However morphine clearance Mousavi et al / DARU 2011 19 (5) 312-321 315
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in general is variable and the range of CL values 
exceed those which were published previously for 
infants who were receiving morphine.
Midazolam is also extensively used as sedative 
in ICU. More than 50% (a loss of 60-95% in 
the  first  hours  after  cannulation)  of  midazolam 
was sequestered during ECMO(PVC circuit and 
silicone oxygenator) so usually higher doses 
is required to achieve adequate sedation. Also 
during the first 24 hrs, because of an expanded 
circulating volume and sequestration by the circuit, 
significantly higher dose of midazolam is required 
to achieve adequate sedation. Ashman et al. (49) 
concluded that clearance of midazolam and its 
metabolite 1-hydroxy midazolam increased 3 folds 
within the first 5 days (as a result of maturation or 
recovery from illness) in neonates, therefore dose 
must be increased subsequently after 5-7 days. 
However large unexplained interpatient variability 
warrants careful titration of sedation and adverse 
effects of midazolam during ECMO. In conclusion, 
volume of distribution and clearance of midazolam 
are higher during ECMO, and absorptive drug loss 
could be a cause of higher dose requirements.
Stress ulcer prophylaxis is necessary for patients 
undergoing ECMO, because of the procedure by 
itself and simultaneous mechanical ventilation and 
anticoagulation. Studies with ranitidine in neonates 
undergoing ECMO show that in spite of greater 
elimination typical dosing regiments were adequate. 
Also continuous infusion and combination of 
motility agents has been recommended in order 
to keep intragastric PH above 4 for prevention of 
upper gastrointestinal bleeding (50, 51). 
Recent review on cardiovascular drug dosing 
in neonates under ECMO,recommended dosing 
modification  for  esmolol,  amiodarone,  nesiritide,   
bumetanid, sildenafil and prostaglandin E1, on the 
basis of changes in of Vd and CL of these drugs 
during ecmo (76) (Table 1). 
CONCLUSION
Although what we have learned from the 
straightforward demographiscs (incidence of 
shock or renal failure, etc) are mostly clear, what 
we have known from drugs› fate from application 
of sophisticated ventilator support techniques are 
not very clear.   In spite of considerable amount of 
pharmacokinetic studies during ECMO, because of 
small sample size, differences in methods and lack 
of control group, developing a guideline for dosing 
of drug during ECMO is difficult. Also because of 
potential changes in drug delivery during ECMO 
along with other changes in pharmacokinetic profile 
of critically ill patients, drug regiments should be 
individualized through therapeutic drug monitoring 
whenever possible, until further studies are carried 
out in this area. Mousavi et al / DARU 2011 19 (5) 312-321 319
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